Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) is now available.
Fusen Pharmaceutical has secured Chinese regulatory approval for its Glucosamine Sulfate Capsule, marketed under the Shuhuitong brand, for treating primary and secondary osteoarthritis. The product, based on natural amino monosaccharides that support cartilage matrix synthesis, is positioned to relieve joint pain, improve function, and slow disease progression in patients needing both short-term relief and long-term maintenance.
Classified as a Class B drug in the national medical insurance catalogue, Glucosamine Sulfate Capsule already represents a sizeable and fast-growing market segment, with category sales exceeding RMB850 million in 2024 and strong double-digit growth into 2025. The launch strengthens Fusen Pharmaceutical’s product pipeline in musculoskeletal care, enhances its presence in the osteoarthritis field, and taps into rising demand driven by China’s aging population and the broader Healthy China policy agenda.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited is a Hong Kong–listed drug maker incorporated in the Cayman Islands, operating through subsidiaries such as Henan Fusen Pharmaceutical in mainland China. The group focuses on developing and marketing prescription medicines in therapeutic areas aligned with long-term demographic trends, targeting the growing demand for chronic disease treatments in the Chinese healthcare market.
Average Trading Volume: 614,368
Technical Sentiment Signal: Buy
Current Market Cap: HK$882.3M
For a thorough assessment of 1652 stock, go to TipRanks’ Stock Analysis page.